LinkedIn Profile

Access XCyton Diagnostics historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal GICS Sector GICS Industry
private:xcytondiagnostics-2 2976613 Jun 4th, 2019 12:00AM XCyton Diagnostics Private Limited 366 30.00 Open Biotechnology Jun 4th, 2019 03:02PM Jun 4th, 2019 03:02PM XCyton is a molecular diagnostics lab & research center providing diagnostic tests in critical infections. We developed & patented 'Syndrome Evaluation System'​ or SES, world's 1st pathogen detection system that simultaneously detects all probable causative agents of critical infections - Bacteria, Fungi, Viruses and Parasites – from a single sample, in a single test, within 7 hrs. SES is for Syndromes likes Sepsis, Pneumonia, Encephalitis, Meningitis, Post Transplant Infections, Uveitis, Endophthalmitis, Retinitis, etc. SES answers these gaps: • Delay: Conventional tests takes >72 hrs SES does it in 7 hrs • Lack of Diagnosis: Conventional tests diagnose in 10-20% cases. SES does it in 70-75% cases • Inability to detect viruses, bacteria, fungi,parasites, etc in one test SES does precisely that • Antibiotic Resistance (ABR) SES detects ABR, helping early initiation of appropriate antibiotic. Guided therapy reduces ABR • Increased health care costs Early diagnosis leads to guided therapy, in turn leading to faster recoveries, reduction in medication, investigations and ICU stay. SES is the only molecular diagnostic test which is proven to reduce mortality, hospital stay & antibiotic usage in sepsis. It is the fastest test available to diagnose pathogens and antibiotic resistance. It specifically identifies pathogenic bugs. It is the only test to identify the exact gene responsible for notoriety of the bug. It is first and only Mol Dx test developed in house to be NABL accredited. XCyton belongs to the top 5% of all Mol Dx labs globally (Validated by QCMD, UK.) More than 300 hospitals in India rely on SES for critical infection diagnosis. We are the Most Awarded Mol Dx Lab in India. Our awards include: * Diagnostic Product of the Year - BioSpectrum * India Innovation Growth Program - DST Lockheed Martin * The Most Important Technology Developed in Asia - Bio Singapore * Technology Business Accelerator Award Winner - XLR8/AP Govt. Open Molecular Diagnostic, Critical Infection Diagnostics, Sepsis Diagnostics, CNS Infection Diagnostics, Eye Infection Diagnostics, Multiplex PCR Open No.449, 10th Cross, 4th Phase, Peenya Industrial Area Bangalore Karnataka IN 560 058 Pharmaceuticals & Biotechnology
private:xcytondiagnostics-2 2976613 Feb 17th, 2018 12:00AM XCyton Diagnostics Private Limited 303 31.00 Open Biotechnology Feb 17th, 2018 02:25PM Feb 17th, 2018 02:25PM XCyton Diagnostics is a revolutionary Molecular Diagnostics Company founded by Dr. B.V. Ravi Kumar. Dr. Kumar, a Physician-Scientist turned technocrat, spearheads a young, dynamic and enthusiastic team of scientists who build products from inventions that are in-house, from academic institutes and/or other industries, leading to the successful creation of scientifically advanced XCyton owned IPRs. XCyton envisions to becoming the global leader in Innovative Diagnostic Product development. with the ambition to highlight India on the world map of Medical diagnostics, and is the catalyst for accurate and time management Diagnostics. XCyton ventured into the conception and invention of Molecular Diagnostic products for improved diagnosis of Critical Care Infections, and developed the unparalleled Syndrome Evaluation System, the world’s first Critical Care Therapeutic Decision Support System. XCyton’s Syndrome Evaluation System (SES) allows for the simultaneous identification of multiple organisms inclusive of Bacteria, Viruses, Fungi and Parasites, in a specific test from a single sample. This process provides the clinician with a rapid, definitive assessment of a patient who is presenting a set of symptoms common to multiple pathogens. XCyton revolutionized Critical Care management through a paradigm shift: from disease-based sequential diagnosis of etiological agents to a syndrome-based assessment which enables physicians to make effective critical therapeutic decisions. Pharmaceuticals & Biotechnology
private:xcytondiagnostics-2 2976613 Feb 16th, 2018 12:00AM XCyton Diagnostics Private Limited 303 31.00 Open Biotechnology Feb 16th, 2017 08:15AM Feb 16th, 2017 08:15AM XCyton Diagnostics is a revolutionary Molecular Diagnostics Company founded by Dr. B.V. Ravi Kumar. Dr. Kumar, a Physician-Scientist turned technocrat, spearheads a young, dynamic and enthusiastic team of scientists who build products from inventions that are in-house, from academic institutes and/or other industries, leading to the successful creation of scientifically advanced XCyton owned IPRs. XCyton envisions to becoming the global leader in Innovative Diagnostic Product development. with the ambition to highlight India on the world map of Medical diagnostics, and is the catalyst for accurate and time management Diagnostics. XCyton ventured into the conception and invention of Molecular Diagnostic products for improved diagnosis of Critical Care Infections, and developed the unparalleled Syndrome Evaluation System, the world’s first Critical Care Therapeutic Decision Support System. XCyton’s Syndrome Evaluation System (SES) allows for the simultaneous identification of multiple organisms inclusive of Bacteria, Viruses, Fungi and Parasites, in a specific test from a single sample. This process provides the clinician with a rapid, definitive assessment of a patient who is presenting a set of symptoms common to multiple pathogens. XCyton revolutionized Critical Care management through a paradigm shift: from disease-based sequential diagnosis of etiological agents to a syndrome-based assessment which enables physicians to make effective critical therapeutic decisions. Pharmaceuticals & Biotechnology
private:xcytondiagnostics-2 2976613 Feb 15th, 2018 12:00AM XCyton Diagnostics Private Limited 303 31.00 Open Biotechnology Feb 15th, 2017 10:07AM Feb 15th, 2017 10:07AM XCyton Diagnostics is a revolutionary Molecular Diagnostics Company founded by Dr. B.V. Ravi Kumar. Dr. Kumar, a Physician-Scientist turned technocrat, spearheads a young, dynamic and enthusiastic team of scientists who build products from inventions that are in-house, from academic institutes and/or other industries, leading to the successful creation of scientifically advanced XCyton owned IPRs. XCyton envisions to becoming the global leader in Innovative Diagnostic Product development. with the ambition to highlight India on the world map of Medical diagnostics, and is the catalyst for accurate and time management Diagnostics. XCyton ventured into the conception and invention of Molecular Diagnostic products for improved diagnosis of Critical Care Infections, and developed the unparalleled Syndrome Evaluation System, the world’s first Critical Care Therapeutic Decision Support System. XCyton’s Syndrome Evaluation System (SES) allows for the simultaneous identification of multiple organisms inclusive of Bacteria, Viruses, Fungi and Parasites, in a specific test from a single sample. This process provides the clinician with a rapid, definitive assessment of a patient who is presenting a set of symptoms common to multiple pathogens. XCyton revolutionized Critical Care management through a paradigm shift: from disease-based sequential diagnosis of etiological agents to a syndrome-based assessment which enables physicians to make effective critical therapeutic decisions. Pharmaceuticals & Biotechnology
private:xcytondiagnostics-2 2976613 Feb 14th, 2018 12:00AM XCyton Diagnostics Private Limited 303 31.00 Open Biotechnology Feb 14th, 2017 01:50PM Feb 14th, 2017 01:50PM XCyton Diagnostics is a revolutionary Molecular Diagnostics Company founded by Dr. B.V. Ravi Kumar. Dr. Kumar, a Physician-Scientist turned technocrat, spearheads a young, dynamic and enthusiastic team of scientists who build products from inventions that are in-house, from academic institutes and/or other industries, leading to the successful creation of scientifically advanced XCyton owned IPRs. XCyton envisions to becoming the global leader in Innovative Diagnostic Product development. with the ambition to highlight India on the world map of Medical diagnostics, and is the catalyst for accurate and time management Diagnostics. XCyton ventured into the conception and invention of Molecular Diagnostic products for improved diagnosis of Critical Care Infections, and developed the unparalleled Syndrome Evaluation System, the world’s first Critical Care Therapeutic Decision Support System. XCyton’s Syndrome Evaluation System (SES) allows for the simultaneous identification of multiple organisms inclusive of Bacteria, Viruses, Fungi and Parasites, in a specific test from a single sample. This process provides the clinician with a rapid, definitive assessment of a patient who is presenting a set of symptoms common to multiple pathogens. XCyton revolutionized Critical Care management through a paradigm shift: from disease-based sequential diagnosis of etiological agents to a syndrome-based assessment which enables physicians to make effective critical therapeutic decisions. Pharmaceuticals & Biotechnology
private:xcytondiagnostics-2 2976613 Feb 13th, 2018 12:00AM XCyton Diagnostics Private Limited 303 31.00 Open Biotechnology Feb 13th, 2017 04:11PM Feb 13th, 2017 04:11PM XCyton Diagnostics is a revolutionary Molecular Diagnostics Company founded by Dr. B.V. Ravi Kumar. Dr. Kumar, a Physician-Scientist turned technocrat, spearheads a young, dynamic and enthusiastic team of scientists who build products from inventions that are in-house, from academic institutes and/or other industries, leading to the successful creation of scientifically advanced XCyton owned IPRs. XCyton envisions to becoming the global leader in Innovative Diagnostic Product development. with the ambition to highlight India on the world map of Medical diagnostics, and is the catalyst for accurate and time management Diagnostics. XCyton ventured into the conception and invention of Molecular Diagnostic products for improved diagnosis of Critical Care Infections, and developed the unparalleled Syndrome Evaluation System, the world’s first Critical Care Therapeutic Decision Support System. XCyton’s Syndrome Evaluation System (SES) allows for the simultaneous identification of multiple organisms inclusive of Bacteria, Viruses, Fungi and Parasites, in a specific test from a single sample. This process provides the clinician with a rapid, definitive assessment of a patient who is presenting a set of symptoms common to multiple pathogens. XCyton revolutionized Critical Care management through a paradigm shift: from disease-based sequential diagnosis of etiological agents to a syndrome-based assessment which enables physicians to make effective critical therapeutic decisions. Pharmaceuticals & Biotechnology
private:xcytondiagnostics-2 2976613 Feb 12th, 2018 12:00AM XCyton Diagnostics Private Limited 303 31.00 Open Biotechnology Feb 12th, 2017 04:15AM Feb 12th, 2017 04:15AM XCyton Diagnostics is a revolutionary Molecular Diagnostics Company founded by Dr. B.V. Ravi Kumar. Dr. Kumar, a Physician-Scientist turned technocrat, spearheads a young, dynamic and enthusiastic team of scientists who build products from inventions that are in-house, from academic institutes and/or other industries, leading to the successful creation of scientifically advanced XCyton owned IPRs. XCyton envisions to becoming the global leader in Innovative Diagnostic Product development. with the ambition to highlight India on the world map of Medical diagnostics, and is the catalyst for accurate and time management Diagnostics. XCyton ventured into the conception and invention of Molecular Diagnostic products for improved diagnosis of Critical Care Infections, and developed the unparalleled Syndrome Evaluation System, the world’s first Critical Care Therapeutic Decision Support System. XCyton’s Syndrome Evaluation System (SES) allows for the simultaneous identification of multiple organisms inclusive of Bacteria, Viruses, Fungi and Parasites, in a specific test from a single sample. This process provides the clinician with a rapid, definitive assessment of a patient who is presenting a set of symptoms common to multiple pathogens. XCyton revolutionized Critical Care management through a paradigm shift: from disease-based sequential diagnosis of etiological agents to a syndrome-based assessment which enables physicians to make effective critical therapeutic decisions. Pharmaceuticals & Biotechnology
private:xcytondiagnostics-2 2976613 Feb 11th, 2018 12:00AM XCyton Diagnostics Private Limited 303 31.00 Open Biotechnology Feb 11th, 2017 05:35AM Feb 11th, 2017 05:35AM XCyton Diagnostics is a revolutionary Molecular Diagnostics Company founded by Dr. B.V. Ravi Kumar. Dr. Kumar, a Physician-Scientist turned technocrat, spearheads a young, dynamic and enthusiastic team of scientists who build products from inventions that are in-house, from academic institutes and/or other industries, leading to the successful creation of scientifically advanced XCyton owned IPRs. XCyton envisions to becoming the global leader in Innovative Diagnostic Product development. with the ambition to highlight India on the world map of Medical diagnostics, and is the catalyst for accurate and time management Diagnostics. XCyton ventured into the conception and invention of Molecular Diagnostic products for improved diagnosis of Critical Care Infections, and developed the unparalleled Syndrome Evaluation System, the world’s first Critical Care Therapeutic Decision Support System. XCyton’s Syndrome Evaluation System (SES) allows for the simultaneous identification of multiple organisms inclusive of Bacteria, Viruses, Fungi and Parasites, in a specific test from a single sample. This process provides the clinician with a rapid, definitive assessment of a patient who is presenting a set of symptoms common to multiple pathogens. XCyton revolutionized Critical Care management through a paradigm shift: from disease-based sequential diagnosis of etiological agents to a syndrome-based assessment which enables physicians to make effective critical therapeutic decisions. Pharmaceuticals & Biotechnology
private:xcytondiagnostics-2 2976613 Feb 10th, 2018 12:00AM XCyton Diagnostics Private Limited 303 31.00 Open Biotechnology Feb 10th, 2017 06:43AM Feb 10th, 2017 06:43AM XCyton Diagnostics is a revolutionary Molecular Diagnostics Company founded by Dr. B.V. Ravi Kumar. Dr. Kumar, a Physician-Scientist turned technocrat, spearheads a young, dynamic and enthusiastic team of scientists who build products from inventions that are in-house, from academic institutes and/or other industries, leading to the successful creation of scientifically advanced XCyton owned IPRs. XCyton envisions to becoming the global leader in Innovative Diagnostic Product development. with the ambition to highlight India on the world map of Medical diagnostics, and is the catalyst for accurate and time management Diagnostics. XCyton ventured into the conception and invention of Molecular Diagnostic products for improved diagnosis of Critical Care Infections, and developed the unparalleled Syndrome Evaluation System, the world’s first Critical Care Therapeutic Decision Support System. XCyton’s Syndrome Evaluation System (SES) allows for the simultaneous identification of multiple organisms inclusive of Bacteria, Viruses, Fungi and Parasites, in a specific test from a single sample. This process provides the clinician with a rapid, definitive assessment of a patient who is presenting a set of symptoms common to multiple pathogens. XCyton revolutionized Critical Care management through a paradigm shift: from disease-based sequential diagnosis of etiological agents to a syndrome-based assessment which enables physicians to make effective critical therapeutic decisions. Pharmaceuticals & Biotechnology
private:xcytondiagnostics-2 2976613 Feb 9th, 2018 12:00AM XCyton Diagnostics Private Limited 303 31.00 Open Biotechnology Feb 9th, 2017 08:57AM Feb 9th, 2017 08:57AM XCyton Diagnostics is a revolutionary Molecular Diagnostics Company founded by Dr. B.V. Ravi Kumar. Dr. Kumar, a Physician-Scientist turned technocrat, spearheads a young, dynamic and enthusiastic team of scientists who build products from inventions that are in-house, from academic institutes and/or other industries, leading to the successful creation of scientifically advanced XCyton owned IPRs. XCyton envisions to becoming the global leader in Innovative Diagnostic Product development. with the ambition to highlight India on the world map of Medical diagnostics, and is the catalyst for accurate and time management Diagnostics. XCyton ventured into the conception and invention of Molecular Diagnostic products for improved diagnosis of Critical Care Infections, and developed the unparalleled Syndrome Evaluation System, the world’s first Critical Care Therapeutic Decision Support System. XCyton’s Syndrome Evaluation System (SES) allows for the simultaneous identification of multiple organisms inclusive of Bacteria, Viruses, Fungi and Parasites, in a specific test from a single sample. This process provides the clinician with a rapid, definitive assessment of a patient who is presenting a set of symptoms common to multiple pathogens. XCyton revolutionized Critical Care management through a paradigm shift: from disease-based sequential diagnosis of etiological agents to a syndrome-based assessment which enables physicians to make effective critical therapeutic decisions. Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.